⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANRO News
Alto Neuroscience Inc.
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
businesswire.com
ANRO
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
prnewswire.com
ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
businesswire.com
ANRO
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
businesswire.com
ANRO
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
prnewswire.com
ANRO
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
prnewswire.com
ANRO
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
prnewswire.com
ANRO
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
prnewswire.com
ANRO
The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
prnewswire.com
ANRO
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
ANRO